John H. Rundback
John H. Rundback has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
Kevin Herman
NJ Endovasc & Amputat Prevent, 347 Mt Pleasant Ave,Suite 100, West Orange, NJ 07052 USA
4 shared publications- Eric A. Secemsky
Harvard Medical School
2 shared publications - Nicolas W. Shammas
Midwest Cardiovascular Research Foundation, Iowa, United States
2 shared publications Prakash Krishnan
Mount Sinai Hospital
2 shared publications- Abhishek Kumar
Rutgers New Jersey Medical School
1 shared publication - Abigail Mize
Advanced Cardiac and Vascular Centers
1 shared publication
Latest Publications
- Open Access
- 18 June 2026
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 5 (7) , 105458
Contemporary Indications for Bioresorbable Scaffolds for Infrapopliteal Peripheral Artery Disease: An International Expert Consensus
- 18 June 2026
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 5 (7) , 105458
Open AccessContemporary Indications for Bioresorbable Scaffolds for Infrapopliteal Peripheral Artery Disease: An International Expert Consensus
- Open Access
- 20 January 2026
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 72 (3) , 503-510
Pedal Venous Maturation on Duplex Ultrasound Predicts Outcomes after Venous Arterialisation in No Option Chronic Limb Threatening Ischaemia
- 20 January 2026
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 72 (3) , 503-510
Open AccessPedal Venous Maturation on Duplex Ultrasound Predicts Outcomes after Venous Arterialisation in No Option Chronic Limb Threatening Ischaemia
- 1 June 2024
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 80 (5) , 1507-1514
Comparison of outcomes of percutaneous deep venous arterialization in multiple practice settings
- 1 June 2024
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 80 (5) , 1507-1514
Comparison of outcomes of percutaneous deep venous arterialization in multiple practice settings
- Open Access
- 2 April 2024
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 103 (6) , 949-962
Solid state, pulsed‐wave 355 nm UV laser atherectomy debulking in the treatment of infrainguinal peripheral arterial disease: The Pathfinder Registry
Background: Atherectomy is an important option for debulking atherosclerotic plaque from diseased arteries in patients with infrainguinal arterial disease. Laser atherectomy uses a high‐powered laser to remove the plaque from the arteries to restore blood flow.Aims: The Pathfinder multicenter registry was initiated to evaluate the safety and efficacy of the 355 nm laser atherectomy system in a real‐world setting for the treatment of de novo, re‐stenotic and in‐stent restenosis (ISR) lesions in infrainguinal arteries of patients with peripheral artery disease (PAD).Methods: The study was a prospective, single‐arm, multicenter, open‐label registry study for patients treated with the 355 nm laser system. Clinical and lesion characteristics, procedural safety and efficacy data, and baseline, 6‐, and 12‐month outcomes data, including Ankle Brachial Index (ABI), Rutherford class, and Walking Impairment Questionnaires (WIQ), were collected. The primary efficacy endpoint was the achievement of ≤30% final residual stenosis at the index lesion postatherectomy and adjunctive therapy evaluated by an angiographic Core Lab. The primary safety endpoint was the percentage of subjects who did not experience periprocedural major adverse events (PPMAEs) before discharge.Results: One hundred and two subjects with 121 lesions treated with the 355 nm laser device at 10 centers were included in the analysis. Mean age was 68.4 ± 10.21 years, 61.8% of subjects were male, 44.6% had critical limb ischemia (CLI), and 47.3% had tibial lesions. The mean residual stenosis at the end of the procedure was 24.4 ± 15.5 with 69 lesions (69.0%) achieving technical procedural success (<30% stenosis); similar rates were observed for subjects with ISR (25.5 ± 14.9), chronic total occlusion (CTO) (28.1 ± 17.0), and severe calcification (36.5 ± 21.6) lesions. Mean ABI, Rutherford, and WIQ scores were improved at both 6 and 12 months. Ninety‐seven of 102 subjects (95.1%) met the primary safety endpoint of not experiencing a PPMAE before discharge.Conclusions: The initial data from the Pathfinder Registry demonstrates the 355 nm laser system is safe and effective in a real‐world setting for performing atherectomy in patients with infrainguinal PAD.
- 2 April 2024
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 103 (6) , 949-962
Open AccessSolid state, pulsed‐wave 355 nm UV laser atherectomy debulking in the treatment of infrainguinal peripheral arterial disease: The Pathfinder Registry
Background: Atherectomy is an important option for debulking atherosclerotic plaque from diseased arteries in patients with infrainguinal arterial disease. Laser atherectomy uses a high‐powered laser to remove the plaque from the arteries to restore blood flow.Aims: The Pathfinder multicenter registry was initiated to evaluate the safety and efficacy of the 355 nm laser atherectomy system in a real‐world setting for the treatment of de novo, re‐stenotic and in‐stent restenosis (ISR) lesions in infrainguinal arteries of patients with peripheral artery disease (PAD).Methods: The study was a prospective, single‐arm, multicenter, open‐label registry study for patients treated with the 355 nm laser system. Clinical and lesion characteristics, procedural safety and efficacy data, and baseline, 6‐, and 12‐month outcomes data, including Ankle Brachial Index (ABI), Rutherford class, and Walking Impairment Questionnaires (WIQ), were collected. The primary efficacy endpoint was the achievement of ≤30% final residual stenosis at the index lesion postatherectomy and adjunctive therapy evaluated by an angiographic Core Lab. The primary safety endpoint was the percentage of subjects who did not experience periprocedural major adverse events (PPMAEs) before discharge.Results: One hundred and two subjects with 121 lesions treated with the 355 nm laser device at 10 centers were included in the analysis. Mean age was 68.4 ± 10.21 years, 61.8% of subjects were male, 44.6% had critical limb ischemia (CLI), and 47.3% had tibial lesions. The mean residual stenosis at the end of the procedure was 24.4 ± 15.5 with 69 lesions (69.0%) achieving technical procedural success (<30% stenosis); similar rates were observed for subjects with ISR (25.5 ± 14.9), chronic total occlusion (CTO) (28.1 ± 17.0), and severe calcification (36.5 ± 21.6) lesions. Mean ABI, Rutherford, and WIQ scores were improved at both 6 and 12 months. Ninety‐seven of 102 subjects (95.1%) met the primary safety endpoint of not experiencing a PPMAE before discharge.Conclusions: The initial data from the Pathfinder Registry demonstrates the 355 nm laser system is safe and effective in a real‐world setting for performing atherectomy in patients with infrainguinal PAD.
- 14 October 2023
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 35 (2) , 278-284
Percutaneous Deep Venous Arterialization in Patients with No-Option Critical Limb Ischemia Performed in an Office-Based Laboratory Setting
- 14 October 2023
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 35 (2) , 278-284
Percutaneous Deep Venous Arterialization in Patients with No-Option Critical Limb Ischemia Performed in an Office-Based Laboratory Setting
- Open Access
- 19 May 2023
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 2 (4)
Evaluation of an Infrapopliteal Drug-Eluting Resorbable Scaffold: Design Methodology for the LIFE-BTK Randomized Controlled Trial
- 19 May 2023
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 2 (4)
Open AccessEvaluation of an Infrapopliteal Drug-Eluting Resorbable Scaffold: Design Methodology for the LIFE-BTK Randomized Controlled Trial
- 1 May 2023
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 220 (5) , 642-643
Atherectomy Before Angioplasty or Stenting for Peripheral Arterial Disease: Point—The Data Indicate That Atherectomy Before Definitive Endovascular Therapy Is Beneficial
This article does not include an Please see the accompanying Counterpoint by Constantino S. Peña.
- 1 May 2023
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 220 (5) , 642-643
Atherectomy Before Angioplasty or Stenting for Peripheral Arterial Disease: Point—The Data Indicate That Atherectomy Before Definitive Endovascular Therapy Is Beneficial
This article does not include an Please see the accompanying Counterpoint by Constantino S. Peña.
- 1 April 2023
- Published by Georg Thieme Verlag KG in Seminars in Interventional Radiology
- Vol. 40 (02) , 183-192
Deep Venous Arterialization: Background, Patient Selection, Technique, Outcomes and Follow-up, and Future Implementation
Critical limb-threatening ischemia (CLTI) is a severe manifestation of peripheral arterial disease with a highly increased risk for morbidity and mortality that has limited and suboptimal opportunities for treatment, ultimately resulting in major amputation for patients. Deep venous arterialization (DVA) provides a suitable limb salvage option for “no-option” patients facing amputation by introducing an artificial anastomosis between a site of proximal arterial inflow and retrograde venous outflow to deliver tissue perfusion to lower extremity wounds. Because DVAs are employed as a last-resort effort in CLTI patients, it is important to provide updated information on indications for usage, strategies in creating DVA conduits, and discussion of outcomes and expectations for patients undergoing this procedure. Additionally, variations in method, including use of various techniques and devices, are explored. The authors provide an up-to-date review of the literature and discuss pertinent procedural and technical considerations for utilizing DVAs in CLTI patients.
- 1 April 2023
- Published by Georg Thieme Verlag KG in Seminars in Interventional Radiology
- Vol. 40 (02) , 183-192
Deep Venous Arterialization: Background, Patient Selection, Technique, Outcomes and Follow-up, and Future Implementation
Critical limb-threatening ischemia (CLTI) is a severe manifestation of peripheral arterial disease with a highly increased risk for morbidity and mortality that has limited and suboptimal opportunities for treatment, ultimately resulting in major amputation for patients. Deep venous arterialization (DVA) provides a suitable limb salvage option for “no-option” patients facing amputation by introducing an artificial anastomosis between a site of proximal arterial inflow and retrograde venous outflow to deliver tissue perfusion to lower extremity wounds. Because DVAs are employed as a last-resort effort in CLTI patients, it is important to provide updated information on indications for usage, strategies in creating DVA conduits, and discussion of outcomes and expectations for patients undergoing this procedure. Additionally, variations in method, including use of various techniques and devices, are explored. The authors provide an up-to-date review of the literature and discuss pertinent procedural and technical considerations for utilizing DVAs in CLTI patients.